Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Lexaria Bioscience (LEXX) Raw Materials (2018 - 2019)

Lexaria Bioscience's Raw Materials history spans 2 years, with the latest figure at $40675.0 for Q1 2019.

On a quarterly basis, Raw Materials changed N/A to $40675.0 in Q1 2019 year-over-year; TTM through Feb 2019 was $40675.0, a N/A change, with the full-year FY2018 number at $29355.0, changed N/A from a year prior.
Raw Materials hit $40675.0 in Q1 2019 for Lexaria Bioscience, up from $29355.0 in the prior quarter.
Over the last five years, Raw Materials for LEXX hit a ceiling of $40675.0 in Q1 2019 and a floor of $29355.0 in Q3 2018.